X @Bloomberg

Novo Nordisk is predicting a 13% drop in sales in 2026. As the company’s patents on Ozempic expire, could cheaper, generic versions give the company a run for its money? Big Take host @davidgura talks to Bloomberg reporters @naomikresge and @AmberTongPW about what comes next https://t.co/HV0Hv3lWMT ...